Iron-(Fe3+) dependent reactivation of telomerase drives colorectal cancers
- Cancer Discov. 2024 Jun 14. doi: 10.1158/2159-8290.CD-23-1379.
- 1. Institute of Molecular and Cell Biology, Singapore, Singapore.
- 2. Institute of Molecular and Cell Biology, Singapore.
- 3. Genome Institute of Singapore, Singapore, Singapore.
- 4. Laboratory of NFκB Signalling, Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore 138673, Singapore, Singapore, Singapore.
- 5. Genome Institute of Singapore, Singapore.
- 6. Singapore General Hospital, Singapore, Singapore.
- 7. Singapore General Hospital, Singapore.
- 8. National Cancer Centre Singapore, Singapore.
- 9. National Cancer Centre Singapore, Singapore, Singapore.
- 10. Experimental Drug Development Centre, Singapore.
- 11. Southern University of Science and Technology, China.
- 12. Laboratory of NF- kappaB signalling, Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673., Singapore, Singapore.
Over-consumption of iron-rich red meat and hereditary or genetic iron overload are associated with increased risk of colorectal carcinogenesis, yet the mechanistic basis of how metal-mediated signaling leads to oncogenesis remains enigmatic. Using fresh colorectal Cancer (CRC) samples we identify Pirin, an iron sensor, that overcomes a rate-limiting step in oncogenesis, by re-activating the dormant human-reverse-transcriptase (hTERT) subunit of Telomerase holoenzyme in an iron-(Fe3+)-dependent-manner and thereby drives CRCs. Chemical genetic screens combined with isothermal-dose response fingerprinting and mass-spectrometry identified a small molecule SP2509, that specifically inhibits Pirin-mediated hTERT reactivation in CRCs by competing with iron-(Fe3+) binding. Our findings, first to document how metal ions reactivate Telomerase, provide a molecular mechanism for the well-known association between red meat, and increased incidence of CRCs. Small molecules like SP2509 represent a novel modality to target Telomerase that acts as driver of 90% human cancers and is yet to be targeted in clinic.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer